Versant Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.4K | Buy |
210
+14
| +7% | +$1.12K | ﹤0.01% | 2001 |
|
|
2026
Q1 | $15.1K | Buy |
196
+8
| +4% | +$624 | ﹤0.01% | 1957 |
|
|
2025
Q4 | $14.8K | Hold |
188
| – | – | ﹤0.01% | 1813 |
|
|
2025
Q3 | $17.2K | Hold |
188
| – | – | ﹤0.01% | 1671 |
|
|
2025
Q2 | $12.3K | Buy |
188
+128
| +213% | +$8.33K | ﹤0.01% | 1798 |
|
|
2025
Q1 | $4.02K | Hold |
60
| – | – | ﹤0.01% | 2101 |
|
|
2024
Q4 | $3.32K | Hold |
60
| – | – | ﹤0.01% | 1937 |
|
|
2024
Q3 | $3.58K | Hold |
60
| – | – | ﹤0.01% | 1389 |
|
|
2024
Q2 | $3.82K | Hold |
60
| – | – | ﹤0.01% | 1305 |
|
|
2024
Q1 | $4.15K | Sell |
60
-13
| -18% | -$785 | ﹤0.01% | 1100 |
|
|
2023
Q4 | $4.03K | Hold |
73
| – | – | ﹤0.01% | 1041 |
|
|
2023
Q3 | $4.24K | Hold |
73
| – | – | ﹤0.01% | 1040 |
|
|
2023
Q2 | $3.93K | Hold |
73
| – | – | ﹤0.01% | 1123 |
|
|
2023
Q1 | $2.9K | Hold |
73
| – | – | ﹤0.01% | 1156 |
|
|
2022
Q4 | $2.94K | Buy |
73
+13
| +22% | +$488 | ﹤0.01% | 1049 |
|
|
2022
Q3 | $2K | Hold |
60
| – | – | ﹤0.01% | 1042 |
|
|
2022
Q2 | $2K | Hold |
60
| – | – | ﹤0.01% | 1061 |
|
|
2022
Q1 | $2K | Sell |
60
-42
| -41% | -$1.57K | ﹤0.01% | 1100 |
|
|
2021
Q4 | $5K | Buy |
+102
| New | +$4.38K | ﹤0.01% | 875 |
|
|
2021
Q3 | – | Sell |
-40
| Closed | -$1K | – | 1438 |
|
|
2021
Q2 | $1K | Buy |
+40
| New | +$1.36K | ﹤0.01% | 1226 |
|
|
2019
Q2 | – | Sell |
-10
| Closed | – | – | 1390 |
|
|
2019
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 1547 |
|
|
2018
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 1463 |
|
|
2018
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 1508 |
|
|
2018
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 1497 |
|
|
2018
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 1475 |
|
|
2017
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 1518 |
|
|
2017
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 1434 |
|
|
2017
Q2 | $0 | Sell |
10
-16
| -62% | -$772 | ﹤0.01% | 1426 |
|
|
2017
Q1 | $1K | Sell |
26
-34
| -57% | -$1.91K | ﹤0.01% | 1304 |
|
|
2016
Q4 | $3K | Buy |
60
+26
| +76% | +$1.59K | ﹤0.01% | 1105 |
|
|
2016
Q3 | $2K | Buy |
34
+1
| +3% | +$63 | ﹤0.01% | 1154 |
|
|
2016
Q2 | $1K | Buy |
33
+26
| +371% | +$1.26K | ﹤0.01% | 1211 |
|
|
2016
Q1 | $0 | Buy |
+7
| New | +$237 | ﹤0.01% | 1325 |
|
Other funds holding ANIP
SCM
TCM
GACM
Versant Capital Management's ANIP Position: Q2 2026 in Review
Versant Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 7.1% in Q2 2026, buying an estimated $1.12K and bringing the position to 210 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2001.
Versant Capital Management first reported a position in ANIP in Q1 2016 and has held it in 33 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- Versant Capital Management held 210 shares of ANI Pharmaceuticals worth $17.4K as of Q2 2026.
- Versant Capital Management bought 14 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.12K.
- ANI Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2001 holding.
- Versant Capital Management first reported a position in ANI Pharmaceuticals in Q1 2016 and has held it in 33 quarters since.
- 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.